Fallopian tube disorder

This trial tests a drug called sacituzumab govitecan in people with advanced or recurrent ovarian, fallopian tube, or primary peritoneal cancer that has high levels of a protein called TROP-2. Participants must have already tried standard treatments without success. The drug is g…

This Phase 3 trial compares a new drug called BL-M07D1 against standard chemotherapy in 404 people with HER2-expressing ovarian, fallopian tube, or peritoneal cancer that has become resistant to platinum-based treatment. Participants will receive either BL-M07D1 or one of several…

This phase 2 trial tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy before surgery can improve outcomes for people with advanced ovarian cancer. Participants receive 3-4 cycles of the combination, followed by surgery to rem…

This study tests whether a combination of two immunotherapy drugs (QL1706), a targeted therapy (bevacizumab), and standard chemotherapy can shrink advanced ovarian cancer before surgery. About 36 women with stage III-IV ovarian cancer will receive the treatment every 3 weeks, the…

This study tests a new combination of medicines (BPaLMZ) against the standard treatment for tuberculous meningitis, a serious brain infection. About 240 adults, including those living with HIV, will take part. The goal is to see if the new combo helps more people survive and reco…

This trial tests whether fluzoparib plus bevacizumab works as well as the standard olaparib plus bevacizumab for maintenance therapy in women with HRD-positive advanced ovarian cancer after initial chemotherapy. The study enrolls about 120 participants and tracks how long they st…

This study tests a new drug, ubamatamab, combined with standard chemotherapy drugs (carboplatin, paclitaxel, and bevacizumab) in 43 people with advanced ovarian cancer that did not respond well to initial treatment. The goal is to see if the combination is safe and can shrink tum…

This phase 2 trial is testing a new, intensive treatment plan for 28 people with advanced ovarian cancer. The approach combines chemotherapy given into the abdomen and vein, a special vaccine made from the patient's own immune cells, and the immunotherapy drug Keytruda. The goal …

This large Phase 3 trial will test a new drug called Rina-S, alone or with bevacizumab, against standard platinum-based chemotherapy for women with ovarian cancer that has returned after initial treatment. About 688 participants will be randomly assigned to receive either the new…

This phase II trial compares a new two-drug combination (sacituzumab govitecan plus bevacizumab) against standard chemotherapy (carboplatin, liposomal doxorubicin, and bevacizumab) in 87 women with platinum-sensitive ovarian cancer that has progressed after PARP inhibitor mainten…

This phase 3 trial compares a new drug called Rina-S to standard chemotherapy in 82 people with platinum-resistant ovarian cancer. Participants are randomly assigned to receive either Rina-S or one of four approved chemotherapies. The goal is to see if Rina-S can delay cancer gro…

This phase II trial tests whether an IGFBP-2 vaccine, given after one dose of carboplatin, can stop ovarian cancer from growing in patients whose recurrence is detected only through a blood test. The vaccine helps the immune system target cancer cells, while carboplatin primes th…

This study tests a combination of two drugs, liposomal irinotecan and enlonstobart, in 30 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if the combo can shrink tumors and delay cancer growth. Participants receive treatment every tw…

This study will observe 500 women with ovarian, fallopian tube, or primary peritoneal cancer who are taking the drug senaparib. Researchers will track side effects and how well the drug controls the cancer in real-world conditions, outside of a strict clinical trial. The goal is …

This study tests whether adding losartan, a blood pressure medication, to weekly paclitaxel chemotherapy can shrink tumors in people with ovarian cancer that no longer responds to platinum-based drugs. About 27 adults with advanced ovarian, fallopian tube, or primary peritoneal c…

This early-stage study tests two drugs, CKD-215 and D215, in 24 adults aged 19-75 with advanced BRCA-mutated ovarian, fallopian tube, or primary peritoneal cancer. The goal is to compare how the body processes each drug and check for side effects. Participants will receive both d…

This study tests a combination of three drugs (Benmelstobart, Anlotinib, and low-dose Cyclophosphamide) in 40 women whose ovarian, fallopian tube, or peritoneal cancer has come back. The goal is to see if this mix can keep the cancer from growing for longer. Participants must be …

This study tests a new two-drug combination (Alpibectir and Ethionamide) added to standard treatment for tuberculosis meningitis, a serious brain infection. About 64 adults newly diagnosed with the condition will receive the drugs to see how well they reach the brain and how safe…

This study tests whether adding an experimental immunotherapy (Aitua Combination Antibody) to standard chemotherapy can help shrink advanced ovarian cancer more effectively before surgery. About 82 women with stage IIIC-IV high-grade serous ovarian cancer who cannot have optimal …

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This Phase 2 trial will test a combination of the experimental drug QL1706 with standard chemotherapy or with olaparib and intraperitoneal chemotherapy as a pre-surgery treatment for 50 women with advanced ovarian cancer. The goal is to see if this approach can shrink tumors enou…

This study looks at whether a blood test score (KELIM) can help doctors decide the best time for surgery in people with advanced ovarian cancer. After three rounds of chemotherapy, those with a good score will have surgery right away, while those with a poor score will get more c…

This study tests whether a combination of two drugs (fluzoparib and famitinib) can help keep advanced ovarian cancer from returning after successful initial chemotherapy. About 43 women with stage III-IV ovarian cancer who responded to platinum-based chemo will take these pills d…

This Phase 2 trial tests a new drug called JPI-547 combined with bevacizumab in 81 women with relapsed ovarian cancer who have already been treated with PARP inhibitors and responded to platinum chemotherapy. The study aims to find the best dose and see if the combination helps k…

This study tests two drug combinations (fluzoparib plus famitinib or fluzoparib plus SHR-1701) given before surgery to shrink advanced ovarian cancer in 104 women whose tumors cannot be fully removed right away. The goal is to see how well these treatments work and how safe they …

This study tests an experimental pill called ZL-85FA in people with advanced solid tumors (breast, ovarian, fallopian tube, primary peritoneal, or prostate cancer) that have not responded to standard treatments. The trial has two phases: first, finding a safe dose, then checking …

This study looks at whether a second surgery to remove visible tumors (secondary cytoreductive surgery) after chemotherapy helps women with platinum-sensitive recurrent ovarian cancer. About 160 participants will be randomly assigned to get surgery plus chemo or chemo alone. The …

This study tests whether N-Acetyl-Cysteine (NAC), a supplement, can reduce chemotherapy-related cognitive impairment (often called 'chemo brain') in ovarian cancer patients. About 102 postmenopausal women with advanced ovarian cancer receiving platinum-based chemotherapy will tak…

This study looks at whether hand and foot exercises can reduce nerve pain (numbness, tingling) and improve quality of life in adults aged 65+ with gynecological cancer who are on chemotherapy. About 74 participants will do these exercises to see if they help with chemotherapy sid…

This study will develop and test a free, cloud-based platform to educate women aged 18-45 with early-stage gynecologic cancer about fertility preservation options. Researchers will compare awareness, knowledge, and attitudes between a group using the platform and a group receivin…

This study looks at tissue samples from 200 people with relapsed ovarian, fallopian tube, or primary peritoneal cancer to see how often a protein called folate receptor alpha (FRα) is present at high levels. The goal is to understand how common this protein is, which may help doc…

This study examines if different eating patterns, especially low-carbohydrate diets, are linked to better outcomes in women with high-grade serous ovarian cancer who are on maintenance therapy with PARP inhibitors. Researchers will review medical records and survey 600 patients f…